Navigation Links
Analysis of Caliper's Phase I EPA ToxCast™ Data Published in Leading Scientific Journal
Date:2/24/2011

HOPKINTON, Mass., Feb. 24, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), today announced that the results of its initial screening efforts under the U.S. Environmental Protection Agency's (EPA) ToxCast program have been published in the scientific journal Toxicology. Key findings reported include (1) a high level of quality and reproducibility in the dataset allowing for robust statistical analyses, and (2) the role that specific targets in biological pathways could play in toxicity events. These findings underscore the success of the Phase I ToxCast effort and support continued expansion of the program to build predictive models for identifying chemicals with high risk for human toxicity or environmental hazard.  Caliper has recently been awarded three new task orders with an aggregate value of $3.1 million to fund additional activities under the EPA ToxCast program.  

The initial goal of the ToxCast program is to create a database of in vitro (laboratory) assay data on a broad set of compounds for which in vivo (animal) safety data already exists. The Toxicology article covers the first phase of ToxCast data produced by Caliper, which involved more than 93,000 chemical-assay pairs. Caliper has contributed 292 assays, more than half of all of the assays, to the EPA ToxCast program. The long term goal of this program is to identify in vitro assays that can predict toxicity in humans and animals and then employ those predictive tests to supplement or replace existing animal-based tests, thus reducing the cost and improving the speed of regulatory approval of new environmental chemicals.    

The article published in Toxicology (Volume 282, Nos. 1-2, pp. 1-15) is entitled "Activity profiles of 309 ToxCast chemicals evaluated across 292 biochemical targets".  The authors include senior scientific staff from EPA's National Center for Computational Toxicology, as well as Arthur Weissman, Ph.D., who serves as Caliper's Principal Investigator under its contract with the EPA for the ToxCast program.                

"We are pleased with the confirmation of the high quality of our ToxCast data reported in this article, as well as the finding that both previously known and novel targets of signaling pathways potentially involved in toxicity mechanisms were identified. Caliper's LabChip® platform in particular was instrumental in demonstrating some types of both kinase inhibition and kinase activation as possible novel toxicity mechanisms," said David Manyak, Ph.D., Executive Vice President of Caliper. "The new funding commitments from EPA will allow us to generate dose response information for the Phase II screening of 700 additional chemicals now underway, as well support an additional round of compound screening to create more detailed models around specific potential toxicity targets."  

"These results underscore Caliper's strategy to become a leader in personalized medicine tools and CRO services," commented Kevin Hrusovsky, President and Chief Executive Officer.  "As we evolve into companion diagnostics and patient stratification CRO services, we believe our unique ToxCast capability will help identify toxicity biomarkers that have the ability to rescue drugs that had failed due to toxicity but have the ability to be efficacious and safe for a patient population subset.  These data will help us to garner additional interest from pharmaceutical and biotechnology companies as we build these enabling CRO services."

Caliper will be hosting a webinar at 1:00 pm EST today (Thursday, February 24), at which Dr. Weissman will present an overview of predictive toxicology and safety pharmacology research programs and offerings of Caliper's Discovery Alliances and Services (CDAS) business unit. Please register online at www.caliperLS.com/CDAS.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to develop life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results that translate into potential cures for a range of diseases. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, molecular imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

NOTE:  Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc.  ToxCast is a trademark of the U.S. Environmental Protection Agency.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
2. Reportlinker Adds U.S. Pain Management Products & Services: a Market Analysis - 7th Edition
3. Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013
4. Reportlinker Adds Brand Erosion Post-Patent Expiry - An analysis of small molecule brand erosion post-patent expiry
5. Reportlinker Adds Dental Implants and Biomaterials - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
6. Reportlinker Adds Cardiac Rhythm Management (CRM) Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
7. Reportlinker Adds Glucose Monitoring Systems - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
8. Reportlinker Adds Magnetic Resonance Imaging (MRI) Systems - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
9. Reportlinker Adds AstraZeneca PLC Market Share Analysis
10. New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
11. New Software for Improving the Analysis of OCT Images
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
Breaking Medicine News(10 mins):